drugset / Trial / NCT04513340

WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects

NCT04513340

Phase 1 Unknown 8 enrolled Hong Kong WD Pharmaceutical Co., Limited
RandomizedCrossoverOpen-labelTreatment

Summary

The Phase 1 PK study is planned to evaluate the food effect on WD-1603 pharmacokinetics

Timeline

Start
2020-08-13
Primary completion
2020-09-05
Completion
2021-02-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbidopa Unknown 25 mg Oral
Subject Levodopa Small molecule 100 mg Oral

Indications